Eli Lilly to Pay $61 Million in Medicaid Pricing Fraud Suit (1)

Aug. 4, 2022, 3:47 PM UTCUpdated: Aug. 4, 2022, 4:20 PM UTC

An Illinois jury said Eli Lilly and Co. must pay $61 million in a whistleblower’s fraud suit alleging that the company made false claims about pricing under Medicaid’s drug rebate program.

The trebled False Claims Act damages amount would exceed $183 million, plus penalties, according to a Wednesday press release by whistleblower Ronald J. Streck’s law firm, Walden Macht & Haran LLP.

“The jury has spoken. Eli Lilly knowingly violated the False Claims Act and defrauded the Medicaid Program of $61 million in taxpayer money,” said Dan Miller of Walden Macht & Haran LLP, lead counsel for Streck.

“We took ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.